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Morphine and other analgesics bind to and activate the μ-opioid receptor (MOR).  
The opioid receptors belong to the Class A subfamily of G-Protein Coupled Receptors 
(GPCRs).  These are transmembrane proteins with seven helices arranged to form a 
closed bundle with loops that extend both extracellularly and intracellularly.  Activation 
of this family of GPCRs has been shown to involve the change of the χ1 dihedral of a 
tryptophan residue on TMH6, W6.48, from g+ to trans.  The purpose of this project was 
to design a computational model of the MOR and to dock both morphine an agonist, and 
naloxone an antagonist, into the model such that their positions were consistent with their 
pharmacologies.  
 A MOR model was created using the Beta-2-Adrenergic (β 2-AR) crystal 
structure as a template with two major modifications.  First, the Conformational 
Memories (CM) program was used to study the conformations of three transmembrane 
helices (TMH); TMH2, TMH4 and TMH6.  Second, the TMH7/elbow/Hx8 region of the 
β 2-AR  was replaced with that of the adenosine A2A crystal structure because the 
adenosine A2A receptor has the same number of residues in the elbow region as is found 
in the MOR.  Energy minimizations were performed on the MOR bundle in a three step 
process and the ligand binding pocket was identified.  Docking studies suggested that 
naloxone binds in the TMH2-3-6-7 region of the MOR such that the N-allyl group 
sterically prohibits the movement of the χ1 of W6.48, thereby preventing activation of the 
 
 
 
 
receptor.  Morphine was also found to bind in the TMH2-3-6-7 region of the MOR; 
however no portion of the morphine structure could block the movement of the χ1 of 
W6.48, thereby producing no impediment for activation.  These results are consistent 
with the pharmacology of naloxone (MOR antagonist) and morphine (MOR agonist).  
Models created will be used for future mutation studies. 
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CHAPTER I 
INTRODUCTION 
For people suffering from many illnesses, pain management is often one of the 
most difficult aspects of treatment.  Morphine and its derivatives are generally the drugs 
of choice of many physicians and for patients dealing with chronic pain.  However, these 
medications have many side effects including respiratory depression, gastrointestinal 
problems as well as dependence and addiction.  Consequently, the need for a pain 
relieving agent without these side effects is of utmost importance. 
Morphine and other analgesics bind to and activate the μ-opioid receptor (MOR) 
(Raehal and Bohn, 2005).  The opioid receptors, delta, kappa and mu, belong to the Class 
A subfamily of G-Protein Coupled Receptors (GPCRs).   This subfamily is the 
Rhodopsin-like family and the dim light photoreceptor Rhodopsin is the base sequence 
typically used for homology modeling of other receptors in this class.  GPCRs are 
transmembrane proteins with four distinguishing structural characteristics as illustrated in 
Figure 1: 
1. Seven transmembrane α-helices (TMHs) arranged to form a closed bundle 
2. An extracellular N-terminus 
3. Extracellular (EC) and Intracellular (IC) loops that connect each of the seven 
TMHs
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4. An intracellular C-terminus that begins with a short helix oriented parallel to 
the membrane (called Helix 8) 
 
 
Figure 1 The structure of a prototypical Class A GPCR 
 
 
Until recently, the only Class A GPCR x-ray crystal structure available was that 
of rhodopsin (Palczewski et al., 2000).  In 2007-2008, x-ray structures became available 
for the carazolol bound beta-2-adrenergic (β 2-AR) (Cherezov et al., 2007; Rasmussen et 
al., 2007), as well as for the cyanopindolol bound β1-AR (Warne et al., 2008) and the 
ZM241385 bound adenosine A2A receptor (Jaakola et al., 2008).  These structures 
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showed substantial similarity to the earlier rhodopsin structure, but important differences 
are present.  One of the most striking differences can be seen in the positions of TMH1 
and TMH2. The transmembrane helix bundle in the rhodopsin crystal structure is tightly 
packed with TMH1 and TMH2 pulled inwards towards the center of the bundle.  TMH2 
of rhodopsin has a GGXTXT motif which can accommodate larger phi/psi values.  As a 
result, the threonines work with the glycines to support hydrogen bonding and bulky 
residues to help stabilize the helix and bundle (Palczewski et al., 2000).  In the β 2-AR 
crystal structure (Krystek et al., 2006) TMH1 and TMH2 are pulled away from the 
bundle.  This allows more room for both the binding pocket and for TMH7, which is 
pulled away in the β 2-AR bundle.  The GGXTXT motif seen in rhodopsin is absent in β 
2-AR, which instead has a proline at 2.59.  Also, in rhodopsin, TMH4 has two prolines 
side by side at the extracellular end of the helix.  However, TMH4 in the β 2-AR, like the 
mu-opioid receptor (MOR) has only one proline.   
GPCR activation studies have primarily come from biophysical studies of 
rhodopsin and the β 2-AR receptor.  In the inactive or off state (R), there is a salt bridge 
between R3.50 and E6.30 on the intracellular side of the TMH bundle that is called the 
“ionic lock”.  Previous studies indicate that this ionic lock is broken during activation as a 
direct result of TMH 3 and TMH 6 rotating away from each other (Ballesteros et al., 
2001).  In TMH 6 there is also a conformational change due to the helix straightening in 
the highly conserved CWXP hinge region (Farrens et al., 1996; Ghanouni et al., 2001; 
Javitch et al., 1997; Jensen et al., 2001; Lin and Sakmar, 1996; Nakanishi et al., 2006).  
Studies have shown that while the (MOR) does not form an ionic lock at the exact same 
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location as rhodopsin, it does form an ionic lock between R3.50 and T6.34 (Huang et al., 
2002).  In the inactive or R state, it has also been shown that the conformation of a 
tryptophan residue on helix 6, W6.48, is such that the χ1 dihedral angle is in a g+ 
conformation.  This conformation in rhodopsin is due to the close proximity of the beta-
ionone ring of rhodopsin’s covalently bound ligand, 11-cis-retinal to W6.48, such that the 
tryptophan is locked in place (Li et al., 2004; Okada et al., 2002; Palczewski et al., 2000).  
Once light activates the receptor by isomerizing 11-cis retinal to all-trans-retinal, the 
beta-ionone ring moves away from TMH-6 and towards TMH-4, allowing the χ1 of 
W6.48 to undergo a g+  trans conformational change (Shi et al., 2002).  In the β 2-AR, 
Shi and co-workers showed that a rotamer “toggle switch” in TMH6 may modulate the 
proline kink differences in the R and R* bundles.  This toggle switch is comprised of 
three residues on TMH6; C6.47, W6.48 and F6.52 in the β 2-AR.  In the MOR, these 
residues correspond to C6.47, W6.48 and H6.52.  The β 2-AR R state is characterized by 
these three residues having g+/trans/trans χ1 geometry, respectively.  The β 2-AR R* 
state is characterized by these three residues having trans/g+/g+ χ1 geometry (Shi et al., 
2002).   
The opioid receptors bind both peptide and non-peptide ligands.  Naloxone is a 
classic (non-peptide) antagonist of the MOR (see Figure 2).  As such, naloxone is 
currently in use worldwide for people who have overdosed on heroin, cocaine or pain 
killers such as morphine, oxycodone or hydrocodone.  In the MOR, the classical μ 
agonist, morphine, is displaced by naloxone and the receptor is changed to an inactive or 
off state (R).  Naltrexone is another MOR antagonist.  The binding pocket for MOR non-
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peptide ligands is commonly thought to be formed by TMH3, TMH5, TMH6, TMH7 and 
EC Loop 2 (Kane et al., 2006).  However, site-directed mutagenesis studies have shown 
that a tyrosine residue (Y7.43) plays an important role in the binding affinity of both 
morphine and naloxone (Mansour et al., 1997).  When residue 7.43 was mutated to a 
phenylalanine, both morphine and naloxone had decreased binding affinities, likely due 
to the loss of a hydrogen bond between Y7.43 and the ligands.  Based on available 
models, using a rhodopsin template, this residue is not thought to be near the binding 
pocket predicted by Kane in 2006 (Hurst, 2008).  As illustrated in Figure 2, naloxone and 
morphine are structurally very similar molecules with the largest difference being the N-
17-substituent which is an N-methyl for morphine, but enlarged to an N-allyl in 
naloxone.  The hypothesis to be tested in the work proposed here is that the origin of 
naloxone’s MOR antagonism lies in its N-allyl group.  This group may sterically block 
the W6.48 g+  trans conformational change associated with activation, thus restraining 
the receptor to its inactive R state.   
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Figure 2 Structures of Morphine, Naloxone & Naltrexone 
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In the MOR, it has previously been shown that D3.32 serves as the counter-ion for 
charged amine containing ligands (Surratt et al., 1994).  When the negative charge of the 
aspartic acid was lost upon mutation to an alanine or asparagine, both naloxone and 
morphine had decreased affinities for the receptor (Surratt et al., 1994).  In the docking 
studies reported here, the negatively charged D3.32 will be used as the primary 
interaction site for morphine and naloxone. 
A few years ago, the Ping-Yee Law lab at the University of Minnesota discovered 
single and triple mutations of the MOR at which naloxone behaves as an agonist with 
concomitant production of antinociception (i.e. pain relief) (Portoghese et al., 2003; Yang 
et al., 2003).  The first mutant receptor discovered by the Law lab to have this property 
was a single mutant in which serine 196 (S4.54) was mutated to alanine (S4.54(196A)), 
resulting in partial agonism of naloxone (Yang et al., 2003)  The second mutant receptor, 
was a triple mutant (Claude-Geppert et al., 2005); S4.54(196)A, T7.44(327)A, and 
C7.47(330)S, which resulted in full agonism of naloxone.  Figure 3 illustrates the position 
of each of the mutated residues.  
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Figure 3:  Locations of mutations in a triple mutant MOR 
(Claude-Geppert et al., 2005) 
 
 
Targeted gene therapy studies using the single mutant have indicated that 
naloxone can act as an antinociceptive agent at this mutant in vivo (Chen et al., 2007).  
Because expression of the mutant MOR is targeted to a limited region of the spinal cord, 
administration of naloxone results in native Wild Type MOR’s being antagonized with 
only the localized mutant MORs being activated by naloxone.  The reduced number of 
receptors activated in this paradigm results in no measurable dependence/addiction as 
seen with traditional mu agonists like morphine (Chen et al., 2007). 
It is important to note that the S4.54(196)A and S4.54(196)A/ T7.44(327)A/ 
C7.47(330)S mutants each involve a serine or threonine and surprisingly that none of the 
mutated residues face into the MOR binding pocket (see Figure 3).  Previously it has 
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been shown that serines and threonines can induce conformational changes in 
transmembrane helices.  The hydrogen bonding capacity of Ser/Thr residues in α-helices 
can be satisfied by an intrahelical hydrogen bond interaction, in either the g- or g+ 
conformation, between the O-γ atom and the i-3 or i-4 carbonyl oxygen (Ballesteros et 
al., 2000).  Ser/Thr residues in the g- conformation can induce a bend in an α-helix, and 
we have found that changes in wobble angle and face shift can also occur (Ballesteros et 
al., 2000).    The work described here is intended to serve as groundwork for the ultimate 
determination of the molecular origins of the unusual phenotype of this triple MOR 
mutant.  
 
 
CHAPTER II 
HYPOTHESIS & METHODS 
 
Hypothesis to Be Tested 
This project focused on designing a computational model for the wild-type (WT) 
MOR using current GPCR crystal structures and their structural motifs as templates.  The 
β 2-AR and the adenosine A2A structure played a large role in the model as they were the 
template for transmembrane helices 1-6 (β 2-AR) and helix 7 / elbow region / helix 8 
(adenosine A2A).  The binding pocket was identified and both morphine a mu opioid 
agonist, and naloxone, an antagonist were docked in the resultant model.  Interactions 
that play a role in the binding of both ligands were analyzed to determine key binding 
pocket residues.  The main hypothesis to be tested in the work presented here is that the 
N-allyl group of naloxone sterically blocks the W6.48 g+  trans conformational change 
associated with activation, thus restraining the receptor to its inactive R state.  This model 
will be used in future projects including a project in conjunction with Dr. PY Law to 
determine the molecular origins of the unusual phenotype of the S4.54(196)A/ 
T7.44(327)A/ C7.47(330)S MOR mutant in which naloxone, the classical MOR 
antagonist becomes an agonist (Claude-Geppert et al., 2005). 
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Methods 
 
Initial Model Construction 
The rhodopsin x-ray crystal structure (Palczewski et al., 2000) was originally used 
as the template for building an MOR model.  However, for reasons discussed below, it 
was concluded that the β 2-AR x-ray crystal structure is a better template (Krystek et al., 
2006).  The initial MOR model was constructed by first aligning the μ sequence with that 
of the template using the highly conserved Class A GPCR sequence motifs (TMH3 
E/DRY; TMH6 CWXP; TMH7 NPXXY) or highly conserved residues (N1.50, D2.50, 
W4.50, P5.50) as the alignment guides.  The structure of the template was mutated to the 
corresponding mu residue using Maestro (Schrodinger 2006).  MOR helices were then 
screened for the occurrence of helix deforming residues such as prolines or glycines that 
may cause the MOR helix conformation to deviate from that of the template.  The 
conformations possible for such helices were studied using Conformational Memories 
(see below) and an appropriate substitute helix was incorporated into the model.   
After developing a model based on the β 2-AR crystal structure, it was determined 
that the TMH7, elbow region and Hx8 area needed to be adjusted.  The β 2-AR structure 
only has one residue in the elbow region, whereas the MOR has 2 residues.   To match 
this structural motif in the MOR, the TMH7/elbow/Hx8 region of the adenosine A2A 
receptor was used as the model template (Jaakola et al., 2008).  Therefore the final MOR 
model was constructed using a β 2-AR template for helices 1 through 6 and the adenosine 
A2A template for helix 7, the elbow region and helix 8.   
 
10 
 
 
Amino Acid Numbering System 
In work reported here, the amino acid numbering system proposed by Ballesteros 
and Weinstein (Ballesteros et al., 2001) is used.  In this system, the most highly 
conserved residue in each transmembrane helix is assigned a locant of 0.50.  This number 
is preceded by the helix number and can be followed by the sequence number in 
parentheses.  All other residues are numbered relative to this residue.  For example, the 
most highly conserved residue in TMH2 is D2.50.The alanine residue that immediately 
precedes it in the MOR would be numbered A2.49, while the alanine immediately after it 
would be numbered A2.51. 
 
Torsion Angle Definition  
The nomenclature used herein to describe the rotameric state of the χ1 side chain 
torsion angles is what was described by Shi and co-workers (Shi et al., 2002).  A residue 
is described to have a trans χ1 angle when the location of the heavy atom at the γ position 
is opposite the backbone nitrogen (180°).  A residue is described to be gauche+ (g+) when 
the γ heavy atom is opposite the backbone carbon and has an angle of +60° when viewed 
from β-carbon to the α-carbon, while it is described as a gauche-(g- ) χ1 angle when the γ 
heavy atom is opposite the α-hydrogen when viewed from the β-carbon to the α-carbon at 
-60° (Kapur et al., 2007).   
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Conformational Memories (CM) 
The conformational memories (CM) method was used to explore the possible 
conformations of MOR helices that contain helix deforming residues as positions not 
found in the template structures (Konvicka et al., 1998).  This method employs multiple 
Monte Carlo/simulated annealing random walks and the CHARMM force field 
(Konvicka et al., 1998; Whitnell et al., 2008).  The CM method has been shown to 
converge in a practical number of steps and to be capable of overcoming energy barriers 
efficiently. With the CM method, the conformational properties of helices can be fully 
characterized based on their free energies.  This includes both the intrinsic energy of each 
conformational state and the probability that the helix will adopt a specific conformation 
relative to the other accessible conformations in an equilibrated thermodynamic 
ensemble.  This technique explores the low free energy conformations possible for a helix 
of interest using Monte Carlo simulated annealing of side chain dihedrals and bond 
angles, while the backbone dihedrals of each helix were set to the standard φ (-63°) and ψ 
(-41.6°) for transmembrane helices (Ballesteros et al., 2000).  In the Reggio lab, the 
established protocol is to allow all torsion angles to vary ±10°, and to allow a larger 
variation of ±50° in regions containing flexible areas.  These flexible areas are areas 
where there are known helix bending residues such as prolines, glycine's, serines and/or 
threonines (Visiers et al., 2000).  Individual bond angles are allowed to vary ±8.  The CM 
calculation is performed in two phases as described below. 
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Exploratory Phase 
In the CM method, a random walk is used to first identify the region of 
conformational space most probable for each torsion angle and bond angle. The initial 
temperature for each run is 3000 K with 50,000 Monte Carlo steps applied to each torsion 
or bond angle variation with cooling in 18 steps to a final temperature of 310 K. Each 
step consists of varying two dihedrals angles and one bond angle chosen at random from 
the entire set of variable angles. The torsion angles and bond angles are randomly picked 
at each temperature and each move is accepted or rejected using the Metropolis criterion 
(Konvicka et al., 1998). Accepted conformations in the Exploratory Phase are used to 
create “memories” of torsion angles and bond angles that were accepted.  This 
information provides a map of the accessible conformational space of each TMH as a 
function of temperature. 
 
Biased Annealing Phase 
In the second phase of the CM calculations, the only torsion angles and bond 
angles moves attempted are those that would keep the angle in the “populated 
conformational space” mapped in the exploratory phase. The biased annealing phase 
begins at 749.4 K with cooling to 310 K in 7 steps. Finally 105 structures are output at 
310 K. 
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Superimposition and Determination of Helices 
In each study, all 105 output conformers for an individual TMH were 
superimposed onto the corresponding template helix in the model.  For all 
superimpositions described herein the C, Cα and backbone N were used as the basis for 
the superimposition.  The specific ranges of residues superimposed are described in the 
next section.  An appropriate helix conformation was selected based upon the absence of 
Van der Waals overlaps with other helices in the bundle, and upon the appropriate 
wobble angle to accommodate loop inclusion.  The helices studied in Conformational 
Memories were superimposed as described in the next section.   
 
Helices Studied Via Conformational Memories 
Models of TMH2, TMH4 and TMH6 were created using the conformational 
memories (CM) technique. 
 
TMH2:  All GPCR’s are aligned using D2.50 in helix 2 as the alignment guide for 
TMH2.  There is also a proline residue at position 2.58 or 2.59 in most Class A GPCRs.  
In the μ sequence, the proline is located at position 2.58, but in the β 2-AR template 
sequence it is at position 2.59.  This offset by one residue is enough to result in a different 
conformation of TMH2 relative to the β 2-AR template.  To ensure a correct 
conformation of TMH2, CM was used.  The region of i (P2.58) to i-4 (T2.54) was 
considered to be the flexible area.  The residues in this area were allowed to vary by 
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±50°.  The output structures were superimposed onto the β 2-AR template using the C, 
Cα and backbone N atoms of residues A2.38 through L2.57. 
 
TMH4:  In the MOR sequence there is a proline at residue 4.59, however, in the β 2-AR 
sequence the proline is located at 4.60.  As a result, the Conformational Memories 
technique was used to determine a wild-type TMH4 for the current work.  The area 
allowed to vary ±50° was I4.51 to P4.59.  Output CM structures (work done by Hadley 
Iliff) were superimposed onto the β 2-AR template using the C, Cα and backbone N 
atoms of residues R4.40 through N4.49 and a wild-type TMH4 was selected and 
incorporated into the current model.   
 
TMH6:  TMH6 of the MOR contains the Class A GPCR CWXP flexible hinge motif.  
Previous studies have suggested that the W6.48 χ1 is in a g+ position in the R state, and in 
trans in the R* state (Ghanouni et al., 2001; Javitch et al., 1997; Jensen et al., 2001).  An 
ionic lock has been shown to exist between TMH3 and TMH6 in the R state.  This lock 
has been shown to be constituted by R3.50 and T6.34 in the MOR R state (Huang et al., 
2002).  Conformational Memories was used to select an appropriate helix for the wild-
type model (R state).  The i (P6.50) to i-4 (V6.46) region was allowed to vary by ±50°.  
Helices were separated based on the χ1 conformation of W6.48 and the output structures 
with a χ1 in the g+ conformation were superimposed onto the β 2-AR template from 
R6.31 through V6.46 using the C, Cα and backbone N atoms. 
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TMH7:  In Class A GPCRs, TMH7 has a conserved sequence motif of NPXXY.  The 
conserved P is located at 7.50.  The flexible region allowed to vary ±50° in TMH7 was 
Y7.43 to S7.47.  The CM output structures were superimposed onto the β 2-AR template 
from T7.44 to L7.56 using the C, Cα and backbone N atoms.  However, as discussed in 
Chapter III, ultimately the output from CM for TMH 7 had to be discarded and the 
adenosine A2A crystal structure was used as the template for TMH 7. 
 
Building the Bundle & Minimizations 
Building the Bundle 
To build the wild-type MOR, the β 2-AR crystal structure bundle was mutated to 
the MOR sequence.  The CM output helices that had been selected were superimposed 
accordingly, and the bundle was minimized in three steps as described below.  Once it 
was determined that the TMH 7/elbow/Hx 8 region needed to be adjusted, the 
corresponding area of the adenosine A2A bundle was superimposed on the β 2-AR 
template, and then mutated to the MOR sequence.  The bundle was minimized as before.  
 
Minimizations 
Before minimizing, each bundle was pulled apart 3Å away from TMH 3 to allow 
room for the side chains to accommodate each other in the new bundle.  Each residue was 
adjusted manually to its most energetically favorable position, while allowing room for 
all other residues and preventing any Van der Waals conflicts.  The χ1 torsion angles of 
C6.47, W6.48 and H6.52 were adjusted to trans/g+/g+ respectively to be in agreement 
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with the “toggle switch” proposed by Shi and co-workers (Shi et al., 2002).  Also, R3.50 
and T6.34 were oriented towards each other to promote the formation of the ionic lock 
when the bundle was minimized (Huang et al., 2002). Once all Van der Waals overlaps 
had been relieved, the minimization was started using an OPLS_2005 force field, no 
solvent and a distance dependent dielectric.  The minimization was set to converge to 
0.05kJ/mol·Å2.  Once a converged output structure was achieved in step 1, the output was 
used as the input for step 2.  This was repeated for steps 2 and 3.  The final structure used 
was the converged structure from the third step of the minimization. 
Step 1:  All backbone phi / psi dihedrals were constrained with a force of 
500kJ/mol.  The distance between the first nitrogen of the guanidine group of R3.50 and 
the hydroxyl oxygen of T 6.34 was constrained to a distance of 2.8Å ± 0.4Å with a force 
of 15kJ/mol.  The amino acid side chains of each residue were allowed to vary. 
Step 2:  All backbone phi / psi dihedrals were constrained with a force of 
100kJ/mol.  There were no constraints placed on any distances or other angles, and all 
side chain dihedrals were allowed to vary.   
Step 3:   The backbone phi / psi dihedrals had no constraint placed on them.  All 
backbone dihedrals as well as all side chain angles were allowed to vary. 
17 
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Docking Methodology 
Before docking morphine or naloxone, an AM-1-conformational search was be 
performed to identify the global minimum energy conformation of each.  The global min 
was then used for docking studies.   In the MOR, Asp3.32 was used as the primary 
interaction site.  Each ligand was docked using interactive computer graphics via Maestro 
(Schrodinger, 2006).  The resulting ligand/receptor complex was energy minimized using 
CHARMM, in the same 3 step process as described above under minimizations for the 
unoccupied receptor.   
  
Interaction Energy Calculation 
The interaction energy between the ligand (morphine or naloxone) and the 
minimized receptor complexes were calculated using a Molecular Mechanics tool in 
Maestro (Schrodinger, 2006).  The OPLS_2005 force field was used, with no solvent and 
a distance dependent dielectric.  The ligand was identified manually (selected by hand), 
and all residue interactions within 5Å of the ligand were used in the calculation.  
 
 
CHAPTER III 
RESULTS 
 
Conformational Memories (CM) Output 
TMH2 
The β 2-AR receptor and the MOR both lack the GGXTXT motif found in 
Rhodopsin.  Each has a proline near its extracellular end; however this proline is at 2.59 
in β 2-AR and 2.58 in the MOR.  To allow for this difference, CM was used to study the 
conformations of TMH2 in the MOR, and the output structures were superimposed onto 
the β 2-AR template.   
Figures 4a and 4b show the superimposition of the CM output structures for 
TMH2 onto the β 2-AR template.  The yellow helix is the β 2-AR TMH2, while the lime 
green helices are the CM output structures.  It can be seen in Figure 4 that the location of 
the proline in the μ-opioid helices does cause the top (extracellular) end of TMH2 to kink 
back to the interior of the bundle, however, the direction of the kink causes the 
extracellular end of TMH2 to move towards TMH3 in the MOR instead of TMH1 as seen 
in the β 2-AR crystal structure.  This helix (cyan) does not have any Van der Waals 
overlaps that would prevent it from fitting into the MOR bundle, and the selected helix is 
slightly pulled out at the extracellular end. 
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Figure 4: CM output for TMH2 
superimposed on the β 2-AR template. 4a 
(left) shows the CM output for TMH2 
superimposed on the β 2-AR template from 
an extracellular view.  4b (right) shows a 
side view from lipid. 
 
TMH 4 
A wild type TMH4 was selected from the CM output structures initially 
calculated by Hadley Iliff.  While this helix did fit in the initial Rhodopsin template of the 
wild-type MOR, it did not fit in the β 2-AR template due to clashes at the extracellular 
end of the bundle between TMH3 and TMH4.  The second TMH4 chosen was initially 
thought to be a possibility due to the extracellular end being pulled away from TMH3, 
however there were steric interactions that prevented it from working as well.  Also, 
V4.60 sterically forced the χ1 angle of Y3.33 into a g+ conformation, thus not allowing it 
any freedom to move into a trans χ1 angle.  By forcing the tyrosine into a g+ χ1 angle, the 
phenol ring was directly pointed into what had been described in the literature to be the 
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ligand binding pocket (TMH3-5-6) (Kane et al., 2006), and prevented both morphine and 
naloxone from being able to be docked in this region.  The helix chosen that is used in the 
final bundle has a wider turn around S4.53 and S4.54 and is shown in Figure 5 in red.  
Figures 5a (EC view) and 5b (side view) show the output structures (white) superimposed 
onto TMH4 of the β 2-AR  template (lime), the TMH4 originally picked is shown in 
purple, the second possibility in blue and the helix used in the final bundle is shown in 
red.   
 
 
 
 
Figure 5: CM output for TMH4 
superimposed on the β 2-AR template.  5a 
(left): EC view of TMH4 CM output 
(white), the β 2-AR template TMH4 in 
lime, and the first two attempted TMH4s 
in fuchsia and blue. The red helix is the 
final TMH4 selected.  5b (right): Side 
view of TMH4 CM output structures 
superimposed on β 2-AR template. 
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TMH6 
Previous studies have shown that the W6.48 adopts a g+ χ1 torsion angle in the R 
state and a trans χ1 in the R* state (Ballesteros et al., 2001; Krystek et al., 2006; Warne et 
al., 2008).  In order to design an accurate wild type R model, the CM output structures 
were sorted based on the W6.48 χ1 torsion angle before superimposition onto the 
template structure.  The output structures with the W6.48 χ1 in g+ (12 of 105) were 
superimposed using the Cα atoms of R6.31 to V6.46.  The intracellular end of TMH6 in 
the R state was chosen for superimposition since previous studies have shown that TMH6 
rotates away from TMH3 during activation (Ballesteros et al., 2001) and undergoes a 
conformational change during activation as well (Farrens et al., 1996; Ghanouni et al., 
2001; Javitch et al., 1997; Jensen et al., 2001; Lin and Sakmar, 1996; Nakanishi et al., 
2006).  Given that the superimposition was performed on the intracellular end of TMH6, 
the ionic lock area was preserved for the CM output helices.  While the original helix 
chosen, shown in Figure 6 in fuchsia, fit into the bundle, the W6.48 residue was rotated 
somewhat closer to TMH5 than in the β 2-AR template structure (Figure 6, yellow 
W6.48).  W6.48 was not included in the superimposition due to the desire not to bias the 
extracellular end of the bundle.  However, it remained important for the location of 
W6.48 to be similar to that in the β 2-AR structure.  As a result, a different helix was 
chosen from the CM output, shown in orange in Figure. 6.  Figure 6 shows the CM output 
helices in lime superimposed onto the β 2-AR template in yellow.  Asp 3.32 is also 
shown in Figure 6 due to its proximity to W6.48 and importance as the counter-ion.  The 
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fuchsia helix and W6.48 is the original helix chosen for the wild type R bundle, and the 
orange helix and W6.48 represent the helix in the current WT R state MOR model.   
 
 
 
 
Figure 6: CM output for TMH6 
superimposed on the β 2-AR template. 6a 
(left) shows an EC view of the CM output 
structures (lime) and the β 2-AR template 
(yellow) for TMH6.  6b (right): a side view 
from lipid of the CM output structures 
(lime) on the β 2-AR (yellow).   The first 
and final helix chosen for use are shown 
here in fuchsia and orange respectively. 
TMH 7 
Conformational Memories was used to determine a wild-type TMH7 because this 
helix will be of considerable importance to future MOR modeling studies as this is the 
site for two of the three mutations (T7.44A and C7.47S) that changed the MOR 
phenotype for naloxone (Claude-Geppert et al., 2005).  The output helices were 
superimposed on the β 2-AR template from T7.44 to L7.56, on the intracellular end.  By 
superimposing on this area, both the conserved NPXXY regions, as well as the sites of 
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the two mutated residues to be examined in the future are included.  Figures 7a (EC view) 
and 7b (side view from lipid), below, show the CM output structures in white, the β 2-AR 
template TMH 7 in yellow and the TMH 7 chosen for the wild type bundle in cyan.    
 
 
 
 
Figure 7: CM output for TMH7 superimposed on the β 2-AR template.  7a (left) EC view 
of the CM TMH7 (white) with the β 2-AR template (yellow) and the selected TMH7 in 
cyan; 7b (right) a side view from lipid.
Once this helix had been determined, the complete bundle was put together and 
minimized.  However, upon comparison with the β 2-AR crystal structure and the 
previous wild-type R bundle based on rhodopsin, it was apparent that the tyrosine at 7.43 
which normally points into the bundle did not do so in the MOR model.  Figure 8 shows 
an EC view (8a) and a side view from lipid (8b) of Y7.43 in the β 2-AR crystal structure 
(yellow) and the TMH 7 CM output structure (cyan).  As shown, Y7.43 points outward 
between helices 1 and 7 instead of into the bundle as seen in the crystal structure.   
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Figure 8:  View of Y7.43 from the CM TMH7 superimposed onto the β 2-AR crystal 
structure.  8a (left) shows an EC view of Y7.43 in the β 2-AR crystal structure (lime) and 
the CM TMH 7 (cyan) from the WT MOR bundle.  8b (right) shows a side view from 
lipid. 
The position of residues at 7.43 in the rhodopsin (a lysine) and adenosine A2A (a 
histidine) crystal structures were compared to aid in the determination of the proper 
direction of Y7.43 in the MOR sequence.  In both of these crystal structures, as well as 
the β 2-AR crystal structure, the residue located at 7.43 points into the bundle.  Re-
examination of the CM output structures revealed that none of the CM output structures 
had Y7.43 pointing inwards.  Since previous work had demonstrated that both morphine 
and naloxone lost affinity for the MOR when Y7.43 was mutated to a phenylalanine 
(Mansour et al., 1997), it is likely that Y7.43 faces into the bundle.  Also complicating 
the TMH7/elbow/Hx8 region was that the elbow region of the β 2-AR template structure 
only had one residue, whereas the MOR sequence has two residues.  Due to this, other 
crystal structures were examined and the decision was made to use the adenosine A2A 
crystal structure (Jaakola et al., 2008) for the TMH 7/elbow/Hx8 region of the MOR 
model.   
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The adenosine A2A receptor is a Class A GPCR with the conserved NPXXY 
motif in TMH7, as well as two residues in the elbow region connecting TMH 7 and Hx8 
(Jaakola et al., 2008).  Due to the structural similarities, it was determined that it would 
be acceptable to mutate the A2A sequence to the MOR sequence for this region.  
Therefore the adenosine A2A TMH7 was superimposed onto the β 2-AR template 
TMH7, and then mutated to the MOR sequence.  The problem with mimicking the 
location of the 7.43 residue in the known crystal structures versus the Conformational 
Memories output structures appears to be that TMH7 is not completely alpha-helical.  
The crystal structures of the β 2-AR and A2A receptor have water in the middle of their 
TMH bundles, as well as an area of 3.10 helix.  The CM protocol used here assumed, 
however, that TMH7 was solely an alpha-helix.   
 
Preparing the WT MOR Bundle for Minimization 
Once all the helices had been selected from the CM output, and the other helices 
had been mutated to the MOR sequence, the bundle was pulled apart 3Å from TMH 3 
which is the central helix in the TMH bundle due to its extreme tilt.  Since D3.32 was 
identified to be the counter-ion for the two charged ligands being docked, it was 
appropriate to pull the bundle apart away from TMH3 and attempt to resolve all steric 
problems with regards to that specific helix.  Initially two different bundles were made 
based on the conformations of a series of aromatic residues on TMH3; Y3.33, F3.37 and 
F3.41.  Both of these bundles were minimized, which resulted in two templates thought 
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to be suitable for docking.  However, docking attempts proved unsuccessful, and some 
residues appeared to have questionable conformations.   
Using sequence comparisons between the adenosine, rhodopsin and the β 2-AR 
crystal structures, it became clear that some of the residues that had initially presented 
conformational problems could be resolved by comparison with these three GPCR 
structures.  Table 1 shows specific residues that were compared, the sequence to which 
they were compared and the orientation of the specific residue based on the models 
available.   
 
Table 1:  Residue comparisons between the MOR sequence and other GPCRs. This includes 
  the Rhodopsin (Rho), the β2AR, and the Adenosine A2A (A2A) structures. 
MOR Residue 
Comparable 
Residue & 
Sequence(s) 
Orientation of 
Comparable 
Residue 
Notes 
N 1.50 N—β2AR g+  
Y 2.42 F—A2A/ β2AR g+  
Y 3.41 F—A2A g+  
W 4.50 W—A2A/ β2AR g+  
F 5.43 F—Rho g+  
F 5.47 F—Rho/ β2AR Trans  
Y 5.58 Y—A2A/ β2AR 
A2Ag+ 
β 2-AR trans 
Both Pointed Into Bundle 
Between TMH3/TMH6 
W 7.35 W— β2AR Trans  
N 7.45 N—A2A/ β2AR Trans  
N 7.49 N—A2A/ β2AR g+  
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Once the changes to the residues in Table 1 were made to the pulled apart bundle, 
and the toggle switch and the ionic lock residues were in the correct orientation, the new 
bundle was minimized in three steps as described previously.  Figure 9 shows a picture of 
the minimized bundle including the important motifs.  The toggle switch residues, C6.47, 
W6.48 and H6.52 are in purple, the ionic lock residues, R3.50 and T6.34 are in cyan, 
Y7.43 is in lavender, D3.32 (the counter-ion) is in lime, and the aromatics on TMH 3 
(Y3.33, F3.37 and F3.41) are in orange. 
 
Figure 9:  A minimized WT MOR R state bundle.  Shown above is a view from the lipid bilayer of 
the minimized MOR wild type R state bundle.  The ionic lock between R3.50 and T6.34 is shown 
in cyan, toggle switch residues on TMH 6 are shown in purple, the counter-ion for the binding of 
both morphine and naloxone D3.32 is shown in lime, the hydrogen bonding residue Y7.43 is in 
lavender and the aromatics on TMH3 are in orange.
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 After the creation of the MOR R state model, the model was assessed for regions 
into which opioid alkaloid ligands could be docked.  This assessment revealed that the 
TMH 3, 5, 6 and 7 region could not accommodate alkaloid ligands.  This result is in 
contrast to a previous Rhodopsin-based modeling study (Kane et al., 2006).  Instead, the 
TMH 2, 3, 6, and 7 region appeared open for alkaloid binding.  To dock the ligands, the 
bundle was pulled apart 2Å in all directions.  This was different from the initial model 
minimizations in which the bundle was pulled away from TMH3.  In this instance, the 
goal was to enlarge the center of the receptor to aid in docking the ligands, whereas 
before the goal was to alleviate steric clashes between side chains on the helices.  
Naloxone was docked using D3.32 as the primary interaction site.  Once naloxone was 
docked and minimized, morphine was superimposed onto naloxone using the carbon 
atoms and the charged nitrogen atom to ensure proper placement into the starting 
structure.  Figure 10 shows an extracellular view of the starting placement of both 
naloxone (fuchsia) and morphine (cyan) in the 2Å pulled apart bundle.  The 
minimizations proceeded with the three step process described above.  
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Figure 10: A WT MOR R state model with initial positions of morphine and naloxone 
docked.  Shown above from an EC view of the MOR R state model (pulled apart 2Å) 
with the initial positions of both morphine (cyan) and naloxone (fuchsia) overlaid. 
 
WT MOR Bundles with Naloxone and Morphine Docked 
 
Once the morphine/MOR and naloxone/MOR complexes were energy minimized, 
they were both analyzed for key interactions.  Figures 11 and 12 illustrate the final 
minimized ligand/receptor complexes with naloxone in fuchsia (Figure 11) and morphine 
in cyan (Figure 12).   
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Figure 11:  Naloxone (NAX; fuchsia) docked and minimized in the WT MOR R state 
model.   Hydrogen bonds between the side chains of the MOR and naloxone are 
shown with yellow dashed lines.
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Figure 12: Morphine (cyan) docked and minimized in the WT MOR R state model.  
Hydrogen bonds between side chains and morphine are shown with yellow dashed lines. 
The yellow dashed lines indicate hydrogen bonds formed between the MOR and 
each ligand.  The docking studies revealed that naloxone and morphine both dock in the 
same region of MOR, the TMH2-3-6-7 region.  Each ligand can establish hydrogen 
bonding interactions with the MOR and the sets of residues involved in these interactions 
between the naloxone/MOR and morphine/MOR are partially overlapping.  Naloxone 
forms two hydrogen bonds with D3.32, one with the NH+ nitrogen and another with the C 
ring hydroxyl group.  Morphine however, only forms one hydrogen bond with D3.32, via 
the NH+ nitrogen.  The hydroxyl that forms the second hydrogen bond with D3.32 in 
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naloxone is a non-polar hydrogen in morphine off of the C ring (see Figure 2).  On the 
other hand, morphine forms two hydrogen bonds with Q2.60 with both the oxygen in the 
tetrahydrofuran ring and the C ring hydroxyl, but naloxone only forms one hydrogen 
bond with Q2.60 via it’s a ring hydroxyl.  Both morphine and naloxone have a hydrogen 
bond between Y7.43 and the A ring hydroxyl group in the docking studies reported here.  
In the naloxone dock, neither the tetrahydrofuran (THF) oxygen nor the carbonyl oxygen 
on the C ring has a hydrogen bond.  Tables 2 and 3 provide information about the 
geometries of the hydrogen bonds formed in these two complexes.   The superscript “a” 
and “d” designate the residue or atom as the acceptor (a) or donor (d) in each hydrogen 
bond.  It is clear that the geometries of these hydrogen bonds are nearly linear and that 
the hydrogen bonding distances are quite good. 
Also shown in the naloxone dock in Figure 11, Y2.64 and H7.36 form a hydrogen 
bond with each other in the naloxone/MOR complex, as indicated with the yellow dashed 
lines (173.2°, 2.689Å).  However, in the morphine dock (Figure 12), this does not occur.  
The distance from the Cα atoms of Y2.64 and H7.36 is 12.3Å in the naloxone dock, and 
16.3Å in the morphine dock.  As shown in Figure 12, morphine has rotated itself such 
that it forms hydrogen bonds with atoms that naloxone does not.  As a result, it seems 
based on visual inspection that the EC end of TMH7 is pushed out of the bundle to some 
degree in the morphine/MOR complex, as evidenced by the loss of a hydrogen bond 
between Y2.64 and H7.36. 
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  Table 2  Hydrogen Bond Atoms, Angles and Distances for the Naloxone/MOR Complex 
Residue 
Atom of 
Naloxone  
Angle of H-Bond 
Heteroatom-
Heteroatom Distance  
Y7.43 d O a—A Ring 174.4° 2.566Å 
Q2.60 a OH d—A Ring 170.9° 2.565Å 
D3.32 a NH+ d 171.2° 2.529Å 
D3.32 a OH d—C Ring 178.0° 2.383Å 
 
  Table 3 Hydrogen Bond Atoms, Angles and Distances for the Morphine/MOR Complex 
Residue 
Atom of 
Morphine 
 
Angle of H-Bond 
Heteroatom-
Heteroatom Distance  
Y7.43 d O a—A Ring 175.3° 2.634Å 
Q2.60 d O—THF 158.9° 2.687Å 
Q2.60 a OH d—C Ring 177.4° 2.575Å 
D3.32 a NH+ d 174.3° 2.505Å 
 
The central hypothesis of this project is that the N-allyl substituent of naloxone 
sterically blocks the movement of the χ1 angle of W6.48 from g+trans, thus preventing 
the WT MOR R state receptor from becoming activated.  Figure 11 illustrates that in the 
naloxone/MOR complex, the naloxone N-allyl substituent is positioned to prevent the 
W6.48 χ1 from a g+trans movement.  Figure 13 depicts how the naloxone N-allyl 
group is prevented from adopting an alternate conformation by Y3.33.  Shown in this 
figure are naloxone (fuchsia), W6.48 (purple) and Y3.33 (orange) in Van der Waals 
representations.  The yellow stick tryptophan residue illustrates the position of W6.48 if 
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its χ1 undergoes the g+trans movement.  This figure illustrates that the location of 
Y3.33 prohibits any movement of the naloxone N-allyl, thus restraining the movement of 
W6.48 and keeping the MOR in an inactive, R state. 
 
Figure 13: Naloxone (fuchsia), W6.48 (purple) and Y3.33 (orange) in VDW 
representations in the WT MOR model.  The yellow tube representation depicts the 
position that W6.48 would assume if its χ1 angle changed to trans.  This figure illustrates 
that the naloxone N-allyl substituent prevents the W6.48 χ1 g+trans movement and 
that Y3.33 restricts the naloxone N-allyl substituent to its current position.   
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The final docked positions of naloxone and morphine are supported by the 
mutation literature which suggests that D3.32 (Surratt et al., 1994) and Y7.43 (Mansour 
et al., 1997) are important for both naloxone and morphine binding.  For the hypothesis 
tested here to be supported, morphine should not block W6.48 from changing its χ1 
angle in the energy minimized morphine/MOR complex.  The N substituent in morphine 
(methyl group) is much smaller in size compared to that of naloxone (allyl group), see 
Figure 2.  Figure 12 illustrates morphine in an energy minimized MOR bundle.  Here it is 
clear that the N substituent would not block the W6.48 χ1 g+trans movement.   
 
Interaction Energies 
The interaction energies between each docked ligand and the MOR were 
calculated using the final minimized docks.  The electrostatic, Van der Waals (VDW) and 
total energy of all residues within 5Å of the ligands were calculated and are shown in 
Tables 4 (naloxone) and 5 (morphine).  As shown for both ligands, the residue with the 
highest single contribution to the interaction energy is D3.32, the counter-ion.   Hydrogen 
bonds with Q2.60 and Y7.43 also make significant contributions to the interaction 
energies for both ligands.   
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Table 4:  Interaction Energies between Naloxone and Residues within 5Å of a MOR 
Binding Site 
 Electrostatic kJ/mol VDW kJ/mol Total Energy kJ/mol 
W 6.48 3.1645 -10.5648 -7.4003 
N 7.45 -0.2580 -0.8216 -1.0796 
V 3.28 0.2226 -5.8006 -5.5780 
Y 6.54 1.3465 -1.0881 0.2584 
L 2.57 -0.4249 -7.5177 -7.9426 
I 6.45 1.7966 -7.8247 -6.0281 
Y 1.39 -2.6868 -1.1139 -3.8007 
D 3.32 -364.4160 62.6916 -301.7244 
I 7.39 -0.6574 -8.3623 -9.0197 
G 7.42 2.4788 -5.9857 -3.5069 
Y 2.64 0.5300 -0.3670 0.1630 
W 7.35 -0.1730 -0.4675 -0.6405 
Q 2.60 -36.6522 3.6969 -32.9553 
Y 3.33 -0.2129 -5.4663 -5.6792 
V 6.55 1.7830 -2.5514 -0.7684 
M 3.36 -1.2174 -3.0189 -4.2363 
I 3.29 0.7937 -8.4107 -7.6170 
Y 7.43 -59.6656 2.6797 -56.9859 
S 7.46 -1.4809 -0.7276 -2.2085 
   
Total Energy:        
-456.75kJ/mol 
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Table 5 Interaction Energies between Morphine and Residues within 5Å of a MOR Binding 
Site 
Residue Electrostatic kJ/mol VDW kJ/mol Total Energy kJ/mol 
W 6.48 0.2537 -5.7103 -5.4566 
N 7.45 1.0007 -0.5258 0.4749 
C 3.25 -6.4965 -1.1660 -7.6625 
I 3.29 -1.2516 -8.1245 -9.3761 
I 6.45 3.3759 -5.6163 -2.2404 
Y 1.39 -3.7717 -2.4016 -6.1733 
Q 2.60 -58.8832 9.6861 -49.1971 
I 7.39 -1.9547 -9.4002 -11.3549 
D 3.32 -235.2808 22.5292 -212.7516 
G 7.42 -0.8948 -7.5533 -8.4481 
V 3.28 -0.0483 -6.9045 -6.9528 
Y 3.33 -1.0251 -1.8050 -2.8301 
C 7.38 -4.9418 -0.7526 -5.6944 
V 1.42 0.0017 -0.2514 -0.2497 
L 2.57 0.4266 -4.1771 -3.7505 
Y 7.43 -49.3070 -9.2397 -58.5467 
S 7.46 -0.8364 -0.5910 -1.4274 
   
Total Energy:        
-391.64 kJ/mol 
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Summary  
A wild type MOR R state model was constructed using the β 2-AR and adenosine 
A2A crystal structures as templates along with modeled changes to TMH2, TMH4 and 
TMH6 based on output from Conformational Memories calculations.  The ionic lock 
between R3.50 and T6.34 in the MOR model is formed in the unoccupied MOR model 
and with naloxone present.  The binding pocket toggle switch determined to be present in 
the β 2-AR structure, is likely also present in the MOR model, as the same residues are 
present at 6.47 (cysteine) and 6.48 (tryptophan), and both sequences have aromatic 
residues at 6.52 (phenylalanine in β 2-AR and histidine in MOR).  The central hypothesis 
of this project is supported by the final morphine/MOR and naloxone/MOR complexes.  
In these complexes the N-allyl group of naloxone blocks the movement of the χ1 angle of 
W6.48, but the corresponding substituent in morphine, an N-methyl, does not block the 
movement of W6.48.  Key residues involved in the binding of both ligands were found to 
be the counter-ion D3.32, as well as hydrogen bonding residues Q2.60 and Y7.43.  The 
work presented here forms the basis for future studies of the MOR.   
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APPENDIX A
Sequence Alignment 
Rho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M N G T E
Beta-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M
A2A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MOR M D S S A A P T N A S N C T D A L A Y S S C S P A P S P G S W V N L S H L D
N-Ter→ 1 1 1 1 1 1 1 1 1 1 1
2 3 3 3 3 3 3 3 3 3 3
9 0 1 2 3 4 5 6 7 8 9
Rho G P N F Y V P F S N A T G V V R S P F E Y P Q Y Y L A E P W Q F S M L A A Y M
Beta-2 G Q P G N G S A F L L A P N R S H A P D H D V T Q Q R D E V W V V G M G I V M
A2A . . . . . . . . . . . . . . . . . . . . . . . . . . M P I M G S S V Y I T V E
MOR G N L S D P C G P N R T D L G G R D S L C P P T G S P S M I T A I T I M A L Y
N-Ter→ TMH1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
3 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 3 3 4 4 4 4 4 4 4 4 4 4 5
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 8 9 0 1 2 3 4 5 6 7 8 9 0
Rho F L L I V L G F P I N F L T L Y V T V Q H K K L R T P L N Y I L L N L A V A D
Beta-2 S L I V L A I V F G N V L V I T A I A K F E R L Q T V T N Y F I T S L A C A D
A2A L A I A V L A I L G N V L V C W A V W L N S N L Q N V T N Y F V V S L A A A D
MOR S I V C V V G L F G N F L V M Y V I V R Y T K M K T A T N I Y I F N L A L A D
TMH1 IC1 Loop TMH2
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7
Rho L F M V L G G F T S T L Y T S L H G Y F V F G P T G C N L E G F F A T L G G E
Beta-2 L V M G L A V V P F G A A H I L M K M W T F G N F W C E F W T S I D V L C V T
A2A I A V G V L A I P F A I T I S T G F C A A . . C H G C L F I A C F V L V L T Q
MOR A L A T S T L P F Q S V N Y L M G T W P F G . T I L C K I V I S I D Y Y N M F
TMH2 EC1 Loop TMH3
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4
3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 3 3 4 4 4 4 4 4 4 4 4 4
8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 8 9 0 1 2 3 4 5 6 7 8 9
Rho I A L W S L V V L A I E R Y V V V C K P M S N F R F . G E N H A I M G V A F T
Beta-2 A S I E T L C V I A V D R Y F A I T S P F K Y Q S L L T K N K A R V I I L M V
A2A S S I F S L L A I A I D R Y I A I R I P L R Y N G L V T G T R A K G I I A I C
MOR T S I F T L C T M S V D R Y I A V C H P V K A L D F R T P R N A K I I N V C N
TMH 3 E/DRY Motif IC2 Loop TMH4 
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4 4 4 4 4 4 4 4 4 4 4 4 4
5 5 5 5 5 5 5 5 5 5 6 6 6
0 1 2 3 4 5 6 7 8 9 0 1 2
Rho W V M A L A C A A P P L A G W S R Y I P E G L Q C . . . . . . . . . . . S C G
Beta-2 W I V S G L T S F L P I Q M H W Y R A T H Q E A I N C Y A N E T . . . . C C D
A2A W V L S F A I G L T P M L G W N N C G Q P K E G K N H S Q G C G E G Q V A C L
MOR W I L S S A I G L P V M F M A T T K Y R Q G S I . . . . . . . . . . . . D C T
TMH4 EC2 Loop
5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6
6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2
Rho I D Y Y T L K P E V N N E S F V I Y M F V V H F T I P M I I I F F C Y G Q L V
Beta-2 F F T N . . . . . . . . Q A Y A I A S S I V S F Y V P L V I M V F V Y S R V F
A2A F E D V V P M . . . . . N Y M V Y F N F F A C V L V P L L L M L G V Y L R I F
MOR L T F S H P T W Y W E . N L L K I C V F I F A F I M P V L I I T V C Y G L M I
EC2 Loop TMH5
5 5 5 5
6 6 6 6
3 4 5 6
Rho F T V K E A A A Q Q Q E S . . . . . . . . . . . . . . . . . . . . . . . . . A
Beta-2 Q E A K R Q L Q K I D K S E G R F H V Q N L S Q V E Q D G R T G H G L R R S S
A2A L A A R R Q L K Q M E S Q P L P G E R A . . . . . . . . . . . . . . . . . . R
MOR L R L K S V R M L S G S . . . . . . . . . . . . . . . . . . . . . . . . . . K
TMH5 IC3 Loop
6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1
Rho T T Q K A E K E V T R M V I I M V I A F L I C W V P Y A S V A F Y I F T H Q G
Beta-2 K F C L K E H K A L K T L G I I M G T F T L C W L P F F I V N I V H V I Q D N
A2A S T L Q K E V H A A K S L A I I V G L F A L C W L P L H I I N C F T F F C P D
MOR E K D R N L R R I T R M V L V V V A V F I V C W T P I H I Y V I I K A L V T I
IC3 Loop TMH6 CWXP Motif TMH6
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5
2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7
Rho S N F G . . P I F M T I P A F F A K S A A I Y N P V I Y I M M N K Q F R N C M
Beta-2 L I R . . . K E V Y I L L N W I G Y V N S G F N P L I Y C R S P D . F R I A F
A2A C S H A P . L W L M Y L A I V L S H T N S V V N P F I Y A Y R I R E F R Q T F
MOR P E T T F Q T V S W H F C I A L G Y T N S C L N P V L Y A F L D E N F K R C F
EC3 Loop TMH7 NPXXY Motif ↑ ↑ HX8
Elbow
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Rho L T T I C C G K N P L G D D E A S A T V S K T E T S Q V A P A . . . . . . . .
Beta-2 Q E L L C L R R S S L K A Y G N G Y S S N G N T G E Q S G Y H V E Q E K E N K
A2A R K I I R S H V L R Q Q E P F K A A G T S A R V L A A H G S D G E Q V S L R L
MOR R E F C I P T S S N I E Q Q N S T R I R Q N T R D H P S T A N T V D R T N H Q
C-Ter→
Rho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beta-2 L L C E D L P G T E D F V G H Q G T V P S D N I D S Q G R N C S T N D S L L
A2A N G H P P G V W A N G S A P H P E R R P N G . . . . . . . . . . . . . . . .
MOR L E N L E A E T A P L P . . . . . . . . . . . . . . . . . . . . . . . . . .
C-Ter→
Key Colors in TMH portions
Prolines
Sequence Uniprot ID Highly conserved
Reasonably conserved
Rho P08100 Loop gap warning (only used in TMH7 to HX8 elbow)
Beta-2 P07550
MOR P35372 Assorted Motifs: N-ter glycosylation sites, GG motif, and GW motif
A2A P29274 C In a disulfide bridge
C C3.25 disulfide bridge from EC2 Loop
C Internal loop disulfide bridge
X Loop w/helical secondary structure
S Possible phosphorylation site
C Palmitoylation site
Glycosylation Motif is NXS or NXT, and X can't be a Proline
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